Two Onc Docs Updates from #ASCO23: ER+/HER- Localized Breast CA & the NATALEE Trial
Jun 26, 2023
This podcast discusses the management of ER positive HER2 negative breast cancer, including the NATALEE Trial on adding ribocyclib to endocrine therapy. They explore the use of CDK46 inhibitor, compare ribocyclib with aromatase inhibitor alone, and analyze its impact on localized breast cancer treatment. The episode also focuses on optimizing clinical trial design for reliable results and stresses the importance of further research on overall survival data.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 4min
Exploring Current Standard of Care and Interim Analysis of NATALEE Trial in Breast Cancer Treatment
03:39 • 3min
Investigation of Ribocyclib in Breast Cancer Treatment and Critical Appraisal of Trial Results
06:39 • 4min
Optimizing Clinical Trial Design for Reliable Results
10:36 • 8min
Analysis of Ribocyclib Study for Localized Breast Cancer Treatment
18:42 • 5min